NEW YORK, Sept. 5 – Structural Bioinformatics and ChemNavigator have agreed to combine their technologies in order to identify novel drug candidates, SBI announced on Wednesday.
According to the terms of the agreement, SBI and its customers will have access to ChemNavigator’s iResearch System, a database of chemical structures for 2 million drug-like compounds. This information can then be screened against SBI’s own drug-target database of three-dimensional protein structures.
Although financial details were not disclosed, the companies said in a statement that they would share any revenues generated from the combined use of their technologies.
“Screening our compound library against [SBI’s] active sites will result in the quick identification of drug candidates that can be moved into lead optimization programs in months rather than years,” ChemNavigator CEO Scott Hutton said in the statement.
The companies, both based in San Diego, said they initially plan to apply their joint technologies to investigating clinical targets for certain cancers and diabetes.